Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRLHR | P49683 | 14/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.41 |
| ▸ | PDE5A | O76074 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3300847 | 0.95 | PRLHR (0.51) | PRLHRPDE5A | |
| SCHEMBL3297793 | 0.93 | PRLHR (0.50) | PRLHR | |
| SCHEMBL3296941 | 0.91 | PRLHR (0.50) | PRLHRMAPTLMNATP53ALDH1A1 | |
| SCHEMBL3294300 | 0.90 | PRLHR (0.46) | PRLHRMAPTLMNATP53ALDH1A1 | |
| SCHEMBL3295383 | 0.89 | PRLHR (0.49) | PRLHRMAPTLMNATP53ALDH1A1 | |
| SCHEMBL3300072 | 0.89 | PRLHR (0.53) | PRLHRMAPTLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL3299804 | 0.88 | LMNA (0.50) | PRLHRMAPTLMNASMN1; SMN2 | |
| SCHEMBL3299646 | 0.88 | PRLHR (0.49) | PRLHRLMNAALDH1A1NPSR1PDE5A | |
| SCHEMBL3299870 | 0.88 | CDK1 (0.52) | PRLHRMAPTLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL3296546 | 0.87 | PRLHR (0.46) | PRLHRMAPTLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8232282-B2 | Compound having bicyclic pyrimidine structure and pharmaceutical composition comprising the same | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-07-31 | — | — | US | disclosed |
| US-20100093771-A1 | Compound having bicyclic pyrimidine structure and pharmaceutical composition comprising the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-04-15 | — | — | US | disclosed |
| EP-2078719-A1 | COMPOUND HAVING BICYCLIC PYRIMIDINE STRUCTURE AND PHARMACEUTICAL COMPOSITION COMPRISING THE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2009-07-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093771-A1 | Compound having bicyclic pyrimidine structure and pharmaceutical composition comprising the same | GART, MGAT2, MGAT1 | PRLHR 3093/4885MAPT 2514/4885LMNA 510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.